Wyost Alternatives Compared
Wyost | Zometa | Sensipar |
|
---|
Wyost (denosumab) | Zometa (zoledronic acid) | Sensipar (cinacalcet) |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Osteolytic Bone Metastases of Solid Tumors, Giant Cell Tumor of Bone, Hypercalcemia of Malignancy, Osteolytic Bone Lesions of Multiple Myeloma. Wyost may also be used for purposes not... View more |
Prescription only
Zometa is only available as an injection for administration by a healthcare provider and is indicated for the treatment of hypercalcemia associated with cancer, osteolytic bone lesions of multiple... View more |
Prescription only
Prescribed for Primary Hyperparathyroidism, Secondary Hyperparathyroidism, Hypercalcemia of Malignancy. Sensipar may also be used for purposes not listed in this medication guide. |
Related suggestions Hypercalcemia of Malignancy
|
|||||||
More about Wyost (denosumab) | More about Zometa (zoledronic acid) | More about Sensipar (cinacalcet) | ||||||||
Ratings & Reviews | ||||||||||
Be the first to share your experience with this drug. |
Zometa has an average rating of 4.5 out of 10 from a total of 41 ratings on Drugs.com. 30% of reviewers reported a positive effect, while 55% reported a negative effect. |
Sensipar has an average rating of 5.7 out of 10 from a total of 9 ratings on Drugs.com. 44% of reviewers reported a positive effect, while 33% reported a negative effect. |
||||||||
Drug Class | ||||||||||
Side Effects | ||||||||||
See also: Wyost side effects in more detail. |
See also: Zometa side effects in more detail. |
See also: Sensipar side effects in more detail. |
||||||||
Generic Availability | ||||||||||
N/A |
Lower cost generic approved | |||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Sensipar prices |
||||||||
Dosage Form(s) Available | ||||||||||
N/A |
|
|
||||||||
Brand Names | ||||||||||
Other denosumab brands include: Jubbonti, Prolia, Xgeva | Other zoledronic acid brands include: Aclasta, Reclast |
N/A |
||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||
609.6 hours |
N/A |
40 hours |
||||||||
CSA Schedule ** View glossary of terms | ||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 284 drugs are known to interact with Wyost:
|
A total of 122 drugs are known to interact with Zometa:
|
A total of 143 drugs are known to interact with Sensipar:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||
Disease Interactions | ||||||||||
First Approval Date | ||||||||||
March 05, 2024 |
February 22, 2002 |
March 08, 2004 |
||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient resources | ||||||||||
Professional Resources | ||||||||||
N/A |
||||||||||
Related Treatment Guide | ||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.